General
Preferred name
GSK461364
Synonyms
GW843682X ()
KIN001-134 ()
GSK-461364 ()
GSK461364, GSK461364A ()
GSK461364A ()
GSK 461364 ()
GSK-461364A ()
Gsk 461364 ()
P&D ID
PD003618
CAS
929095-18-1
Tags
available
drug candidate
Drug indication
Non-hodgkin lymphoma
Solid tumour/cancer
Drug Status
investigational
Max Phase
Phase 1
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION GSK-461364A is an inhibitor of polo-like kinase 1 (PLK1) . It was tested in preclinical studies. (GtoPdb)
DESCRIPTION inhibitor of polo-like kinase 1 (PLK1) (Informer Set)
Cell lines
4
Organisms
0
Compound Sets
23
AdooQ Bioactive Compound Library
A10442
Axon Medchem Screening Library
1688
Cayman Chemical Bioactives
18099
ChEMBL Drugs
CHEMBL1908394
Clinical kinase drugs
Drug Repurposing Hub
DrugMAP
DM0P729
EU-OPENSCREEN Bioactive Compound Library
EOS101392
EUbOPEN Chemogenomics Library
Guide to Pharmacology
5684
Informer Set
649862
Kinase Chemogenomic Set (KCGS)
GSK461364
Kinase Inhibitors (best-in-class)
LINCS compound set
10013-101
10013-999
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1908394
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL1908394
Mcule NIBR MoA Box Subset
MCULE-2470000007
MedChem Express Bioactive Compound Library
HY-50877
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
GSK461364
TargetMol Bioactive Compound Library
T6282
Welcome Trust Cancer Drugs
87
External IDs
24
Properties
(calculated by RDKit )
Molecular Weight
543.19
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
4
cLogP
5.09
TPSA
76.62
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.35
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PLK1
PLK1, NEK2
Polo-like Kinase (PLK)
PLK
Compound status
clinical
Pathway
mitosis
Cell Cycle/Checkpoint
Cell Cycle/DNA Damage
Member status
member
MOA
PLK1 inhibitor
PLK inhibitor
Therapeutic Class
Anticancer Agents
Source data